Jaguar Health provides recap of presentation on crofelemer results

Jaguar Health’s (JAGX) Napo Pharmaceuticals provided a recap of the November 8, 2025 presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting describing the initial groundbreaking results of an independent investigator-initiated trial of crofelemer in the UAE for treatment of pediatric intestinal failure, which includes patients with ‘intestinal failure’ due to microvillus inclusion disease and short bowel syndrome. “The intestines of patients with the ultrarare genetic disorder MVID do not function properly, as is often the case with patients having intestinal failure due to short bowel syndrome. The intestines of these patients are unable to absorb the fluids, electrolytes and nutrients required to survive and thrive. Intestinal failure is a debilitating, lifelong condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition with supplemental intravenous fluids, which together constitute parenteral support. Most intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day,” said Lisa Conte, Jaguar’s CEO. While crucial for these patients, total parenteral support is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, liver and kidney function problems – as well as a risk of neurodevelopmental delay. These symptoms may emerge at any time in intestinal failure patients, and often become life-threatening. As presented at NASPGHAN, the results of this ongoing and independent proof-of-concept trial of crofelemer demonstrate disease progression modification through reduction of total parenteral support in pediatric intestinal failure patients that ranged from 12 to 37%. Specifically, in the two SBS-IF patients who have completed treatment, the results show crofelemer reduced PS between 12.5 to 15.6% at the highest dose over the 12-week treatment period, together with reduced loose watery stools frequency. For the initial MVID patient who has completed treatment, PS needs were reduced by up to 27% at the highest dose over the initial 12-week treatment period and up to 37% during the extension period upon reinitiation of crofelemer treatment, and also showed reduced frequency of loose watery stools. These findings support continued evaluation of crofelemer to reduce PS needs for pediatric intestinal failure patients. The presentation on November 8, 2025 at NASPGHAN, was titled Exploratory Single-Arm, Open-Label Non-Randomized Trial Evaluating the Safety and Effectiveness of Crofelemer in Pediatric Patients with Intestinal Failure. The study’s primary investigator, Dr. Mohamad Miqdady, Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City, a tertiary care center in Abu Dhabi in the UAE, described these initial findings in pediatric intestinal failure patients with crofelemer treatment.